Atlas Venture

Kymera is a clinical-stage biotechnology company focused on developing innovative medicines through targeted protein degradation, aiming to address critical health problems and improve patients' lives.

Editas Medicine is a pioneering gene editing company focused on developing transformative medicines using CRISPR technology to treat serious diseases.

Alnylam Pharmaceuticals is a leading company in the field of RNA interference (RNAi) therapeutics, focusing on the development of innovative medicines for genetic diseases.

Exelixis is a multi-platform cancer company innovating with small molecules and biotherapeutics to develop a diversified portfolio of cancer treatments.

Horizonte Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for individuals affected by rare and rheumatic diseases.

MorphoSys is a biotechnology company focused on developing innovative therapies. They have conducted research on MOR202 in combination with low-dose dexamethasone and continue to fund and support clinical evaluations of their therapies as of 2026.

Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases.

Harnessing breakthrough science to advance hematology care, focusing on innovative treatments for hematologic diseases.

A biotechnology company developing nucleic acid therapies for rare diseases.

Q32 Bio is focused on developing innovative therapies for autoimmune and inflammatory diseases, particularly targeting immune system rebalancing.

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting the NBD1 region to treat cystic fibrosis (CF) patients.

Akero Therapeutics is focused on developing Efruxifermin (EFX) for the treatment of metabolic diseases, particularly MASH (Metabolic Associated Steatotic Liver Disease).

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.

Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.